Currently, FGF21 is considered an attractive therapeutic target to treat obesity and obesity-associated metabolic disorders, including non-alcoholic fatty liver disease (NAFLD) [1,4,5]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.